Physician profile
Mohammad Etminan
NPI 1972509230
$1,011,246.39
in general payments reported to CMS, 2019-2025
26 companies · $141K in 2025
The $141K reported for 2025 was more than what 94% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $158K · 2021: $130K · 2022: $135K · 2023: $139K · 2024: $102K · 2025: $141K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $248K · Consulting Fee: $130K · Food and Beverage: $3,891 · Travel and Lodging: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $248,291.48 |
| Consulting Fee | $130,000.00 |
| Food and Beverage | $3,891.31 |
| Travel and Lodging | $492.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corelink, LLC | $540,501.30 | 2019-2023 | |
| Zavation Medical Products, LLC | $310,557.94 | 2023-2025 | |
| Alphatec Spine, INC | $153,923.79 | 2019-2024 | Battalion Llif |
| Depuy Synthes Sales INC. | $1,514.93 | 2019-2025 | Symphony, Expedium, Teligen |
| Medtronic, INC. | $633.57 | 2021-2023 | Mazor X System, Swiftset |
| Spineart USA INC | $630.03 | 2019-2024 | |
| Cerapedics INC. | $443.67 | 2022-2024 | I-Factor Peptide Enhanced Bone Graft |
| Providence Medical Technology, INC. | $409.93 | 2020-2025 | |
| Medinc of Texas | $408.83 | 2024 | |
| Relievant Medsystems, INC. | $312.61 | 2021 | |
| Arthrex, INC. | $302.65 | 2024 | |
| Innovasis INC | $283.80 | 2022 | |
| Nuvasive, INC. | $230.55 | 2019 | |
| Si-Bone, INC. | $178.04 | 2024-2025 | |
| Centinel Spine, LLC | $140.05 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kuros Biosciences USA, INC | $123.70 | 2023 | |
| Davol INC. | $117.81 | 2022 | |
| Zimvie INC. | $114.37 | 2023 | |
| Novapproach Spine, LLC | $111.42 | 2024 | Onelif |
| Surgalign Spine Technologies, INC. | $104.98 | 2021 | |
| Intrinsic Therapeutics | $85.36 | 2023 | Barricaid Acd (Annular Closure Device) |
| Pacira Pharmaceuticals Incorporated | $28.78 | 2023 | Zilretta, Iovera, Exparel |
| Zimmer Biomet Holdings, INC. | $28.50 | 2019 | |
| Medtronic USA, INC. | $24.49 | 2020 | |
| Abbott Laboratories | $24.34 | 2023 | Eterna |
| Arteriocyte Medical Systems, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Etminan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.